Importance: Virus infection has been widely described as one of the most common causes of myocarditis. However, less is known about the cardiac involvement as a complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Objective: To describe the presentation of acute myocardial inflammation in a patient with coronavirus disease 2019 (COVID-19) who recovered from the influenzalike syndrome and developed fatigue and signs and symptoms of heart failure a week after upper respiratory tract symptoms.
Design, setting, and participant: This case report describes an otherwise healthy 53-year-old woman who tested positive for COVID-19 and was admitted to the cardiac care unit in March 2020 for acute myopericarditis with systolic dysfunction, confirmed on cardiac magnetic resonance imaging, the week after onset of fever and dry cough due to COVID-19. The patient did not show any respiratory involvement during the clinical course.
Exposure: Cardiac involvement with COVID-19.
Main outcomes and measures: Detection of cardiac involvement with an increase in levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T, echocardiography changes, and diffuse biventricular myocardial edema and late gadolinium enhancement on cardiac magnetic resonance imaging.
Results: An otherwise healthy 53-year-old white woman presented to the emergency department with severe fatigue. She described fever and dry cough the week before. She was afebrile but hypotensive; electrocardiography showed diffuse ST elevation, and elevated high-sensitivity troponin T and NT-proBNP levels were detected. Findings on chest radiography were normal. There was no evidence of obstructive coronary disease on coronary angiography. Based on the COVID-19 outbreak, a nasopharyngeal swab was performed, with a positive result for SARS-CoV-2 on real-time reverse transcriptase-polymerase chain reaction assay. Cardiac magnetic resonance imaging showed increased wall thickness with diffuse biventricular hypokinesis, especially in the apical segments, and severe left ventricular dysfunction (left ventricular ejection fraction of 35%). Short tau inversion recovery and T2-mapping sequences showed marked biventricular myocardial interstitial edema, and there was also diffuse late gadolinium enhancement involving the entire biventricular wall. There was a circumferential pericardial effusion that was most notable around the right cardiac chambers. These findings were all consistent with acute myopericarditis. She was treated with dobutamine, antiviral drugs (lopinavir/ritonavir), steroids, chloroquine, and medical treatment for heart failure, with progressive clinical and instrumental stabilization.
Conclusions and relevance: This case highlights cardiac involvement as a complication associated with COVID-19, even without symptoms and signs of interstitial pneumonia.
[Late gadolinium enhancement and T1 mapping for the diagnosis of cardiac amyloidosis].Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019 Dec;31(12):1538-1541. doi: 10.3760/cma.j.issn.2095-4352.2019.12.021. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 32029045 Chinese.
Myopericarditis in children: elevated troponin I level does not predict outcome.Pediatr Cardiol. 2012 Oct;33(7):1040-5. doi: 10.1007/s00246-012-0222-y. Epub 2012 Feb 10. Pediatr Cardiol. 2012. PMID: 22322566
COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.Cardiovasc Res. 2020 Apr 30:cvaa106. doi: 10.1093/cvr/cvaa106. Online ahead of print. Cardiovasc Res. 2020. PMID: 32352535 Free PMC article.
Biventricular takotsubo cardiomyopathy: case study and review of literature.Tex Heart Inst J. 2013;40(3):305-11. Tex Heart Inst J. 2013. PMID: 23914028 Free PMC article. Review.
COVID-19 (Novel Coronavirus 2019) - recent trends.Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2006-2011. doi: 10.26355/eurrev_202002_20378. Eur Rev Med Pharmacol Sci. 2020. PMID: 32141569 Review.
Cited by 32 articles
An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19).Clin Drug Investig. 2020 May 28:1-11. doi: 10.1007/s40261-020-00927-1. Online ahead of print. Clin Drug Investig. 2020. PMID: 32468425 Free PMC article. Review.
The COVID-19 Pandemic and its Impact on the Cardio-Oncology Population.Curr Oncol Rep. 2020 May 28;22(6):60. doi: 10.1007/s11912-020-00945-4. Curr Oncol Rep. 2020. PMID: 32462289 Free PMC article. Review.
Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation.Clin Res Cardiol. 2020 May 27:1-14. doi: 10.1007/s00392-020-01656-3. Online ahead of print. Clin Res Cardiol. 2020. PMID: 32462267 Free PMC article. Review.
COVID-19: a primer for healthcare providers.Wien Klin Wochenschr. 2020 May 20:1-6. doi: 10.1007/s00508-020-01678-x. Online ahead of print. Wien Klin Wochenschr. 2020. PMID: 32435870 Free PMC article. Review.
Adapting to the Coronavirus Disease 2019 Pandemic in New York City.Am J Phys Med Rehabil. 2020 Jun;99(6):453-458. doi: 10.1097/PHM.0000000000001451. Am J Phys Med Rehabil. 2020. PMID: 32433329 Free PMC article.